Literature DB >> 18490230

Renal oncocytoma: clinical experience of Taipei Veterans General Hospital.

Yu-Hua Fan1, Yen-Hwa Chang, William J S Huang, Hsiao-Jen Chung, Kuang-Kuo Chen.   

Abstract

BACKGROUND: Renal oncocytoma has been reported mostly in the Western literature, and only a few cases have been reported in Eastern populations. In the present study, we review the clinical course of renal oncocytoma in our institution.
METHODS: We obtained the files of 13 cases of renal oncocytoma between 1988 and 2006 from the pathological archives of Taipei Veterans General Hospital. We retrospectively analyzed the patients' characteristics, clinical manifestations, surgical technique and clinical outcome.
RESULTS: The study population comprised 10 men and 3 women, and the mean age at diagnosis was 59.6 years (range, 37-75 years). Twelve patients (92%) were asymptomatic at presentation and were incidentally diagnosed to have renal tumor by sonography (9 patients), computed tomography (1 patient) or magnetic resonance imaging (2 patients), and 1 presented with hematuria. The clinical impression of oncocytoma was made preoperatively in only 3 patients by imaging studies, and most of the patients (76.9%) were diagnosed with renal cell carcinoma before surgery. Ten were treated with radical nephrectomy, 2 with partial nephrectomy, and 1 received excisional biopsy. All patients had unilateral solitary renal tumor; the right kidney was involved in 7 cases (54%) and the left in 6 (46%). Mean tumor size was 5.3 cm (range, 2.7-8.5 cm). Three patients were lost to follow-up in our series, and there was no recurrence or death (100% disease-specific survival) in the remaining 10 patients (77%) who were followed-up for a mean duration of 53.2 months (range, 10-117 months).
CONCLUSION: Renal oncocytoma has a benign clinical course with excellent long-term outcomes. Currently, nephron-sparing surgery is the mainstay of treatment, especially in patients with small tumors. However, accurate preoperative diagnosis based only on imaging studies is difficult, and radical nephrectomy was performed for most of the patients in our series.

Entities:  

Mesh:

Year:  2008        PMID: 18490230     DOI: 10.1016/S1726-4901(08)70116-3

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  7 in total

1.  Incidental Bilateral Renal Oncocytoma in a Patient with Metastatic Carcinoma of Unknown Primary: a Pitfall on (18)F-FDG PET/CT.

Authors:  William Makis; Anthony Ciarallo; Javier-A Novales-Diaz; Robert Lisbona
Journal:  Nucl Med Mol Imaging       Date:  2011-07-13

2.  Renal oncocytoma: A report of two cases and review of the literature.

Authors:  Yuantao Wang; Y U Hu; Xiuyu Zhai; Weigang Wang; Biao Dong; Honglan Zhou
Journal:  Oncol Lett       Date:  2016-05-17       Impact factor: 2.967

3.  Giant renal oncocytoma.

Authors:  Julien Al Shakarchi; Iain Wharton; Amgad Youssef; Paul Anderson
Journal:  Radiol Case Rep       Date:  2015-12-07

4.  A Rare Benign Tumor in a 14-Year-Old Girl.

Authors:  Meral Hassan Abualjadayel; Osama Y Safdar; Maysaa Adnan Banjari; Sherif El Desoky; Ghadeer A Mokhtar; Raed A Azhar
Journal:  Case Rep Nephrol       Date:  2018-01-31

5.  High-Resolution Ultrasonography of Renal Oncocytoma Presenting with Symptomatic Hematuria and Urinary Bladder Clot Retention-A Rare Occurrence.

Authors:  Reddy Ravikanth
Journal:  J Kidney Cancer VHL       Date:  2022-01-01

Review 6.  Renal Oncocytoma: The Diagnostic Challenge to Unmask the Double of Renal Cancer.

Authors:  Francesco Trevisani; Matteo Floris; Roberto Minnei; Alessandra Cinque
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

7.  Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings.

Authors:  Anna K Paschall; Moozhan Nikpanah; Faraz Farhadi; Elizabeth C Jones; Paul G Wakim; Andrew J Dwyer; Rabindra Gautam; Maria J Merino; Ramaprasad Srinivasan; W Marston Linehan; Ashkan A Malayeri
Journal:  Clin Imaging       Date:  2020-06-09       Impact factor: 1.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.